Cytoreductive nephrectomy in the current treatment algorithm

The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether defer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuusk, Teele, Szabados, Bernadett, Liu, Wing Kin, Powles, Thomas, Bex, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767741/
https://www.ncbi.nlm.nih.gov/pubmed/31632471
http://dx.doi.org/10.1177/1758835919879026
_version_ 1783454985114091520
author Kuusk, Teele
Szabados, Bernadett
Liu, Wing Kin
Powles, Thomas
Bex, Axel
author_facet Kuusk, Teele
Szabados, Bernadett
Liu, Wing Kin
Powles, Thomas
Bex, Axel
author_sort Kuusk, Teele
collection PubMed
description The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition.
format Online
Article
Text
id pubmed-6767741
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67677412019-10-18 Cytoreductive nephrectomy in the current treatment algorithm Kuusk, Teele Szabados, Bernadett Liu, Wing Kin Powles, Thomas Bex, Axel Ther Adv Med Oncol Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition. SAGE Publications 2019-09-27 /pmc/articles/PMC6767741/ /pubmed/31632471 http://dx.doi.org/10.1177/1758835919879026 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Kuusk, Teele
Szabados, Bernadett
Liu, Wing Kin
Powles, Thomas
Bex, Axel
Cytoreductive nephrectomy in the current treatment algorithm
title Cytoreductive nephrectomy in the current treatment algorithm
title_full Cytoreductive nephrectomy in the current treatment algorithm
title_fullStr Cytoreductive nephrectomy in the current treatment algorithm
title_full_unstemmed Cytoreductive nephrectomy in the current treatment algorithm
title_short Cytoreductive nephrectomy in the current treatment algorithm
title_sort cytoreductive nephrectomy in the current treatment algorithm
topic Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767741/
https://www.ncbi.nlm.nih.gov/pubmed/31632471
http://dx.doi.org/10.1177/1758835919879026
work_keys_str_mv AT kuuskteele cytoreductivenephrectomyinthecurrenttreatmentalgorithm
AT szabadosbernadett cytoreductivenephrectomyinthecurrenttreatmentalgorithm
AT liuwingkin cytoreductivenephrectomyinthecurrenttreatmentalgorithm
AT powlesthomas cytoreductivenephrectomyinthecurrenttreatmentalgorithm
AT bexaxel cytoreductivenephrectomyinthecurrenttreatmentalgorithm

Ejemplares similares